Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations.

Fulgent Genetics is evolving into a precision medicine player with strong cash reserves, despite expected near-term losses.

Recent advances in RAS-targeted therapies revolutionize treatment for gastrointestinal cancers, promising improved outcomes ...

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

SAN DIEGO, June 13, 2025 /PRNewswire/ — Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was ...

The objective response rate was 65.7% in the encorafenib/cetuximab with mFOLFOX6 arm, compared with 45.6% in the encorafenib/cetuximab alone group and 37.4% in the control arm. Patients in the triplet ...

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance ...

HealthDay News — For patients with BRAF V600E-mutated metastatic colorectal cancer, progression-free and overall survival are significantly longer with encorafenib plus cetuximab (EC) plus ...

Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi (encorafenib), combined with Erbitux (cetuximab) and mFOLFOX6, significantly ...

Braftovi (encorafenib) is indicated, in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an ...